Henry J. Fuchs

2019

In 2019, Henry J. Fuchs earned a total compensation of $7M as President, Worldwide R&D at BioMarin Pharmaceutical, a 21% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$828,000
Option Awards$1,189,277
Salary$695,192
Stock Awards$4,275,463
Other$29,567
Total$7,017,499

Fuchs received $4.3M in stock awards, accounting for 61% of the total pay in 2019.

Fuchs also received $828K in non-equity incentive plan, $1.2M in option awards, $695.2K in salary and $29.6K in other compensation.

Rankings

In 2019, Henry J. Fuchs' compensation ranked 1,369th out of 13,971 executives tracked by ExecPay. In other words, Fuchs earned more than 90.2% of executives.

ClassificationRankingPercentile
All
1,369
out of 13,971
90th
Division
Manufacturing
480
out of 5,701
92nd
Major group
Chemicals And Allied Products
143
out of 2,200
94th
Industry group
Drugs
114
out of 1,886
94th
Industry
Pharmaceutical Preparations
85
out of 1,398
94th

Pay ratio

Henry J. Fuchs' Pay$7,017,499
Median Employee's Pay$190,917
Pay Ratio

37

to 1

In 2019, the annual total compensation of Henry J. Fuchs was $7,017,499.

The annual total compensation of the median employee at BioMarin Pharmaceutical was $190,917.

The ratio of Henry J. Fuchs' pay to the pay of median employee was therefore 37 to one.

Source: SEC filing on April 14, 2020.

Fuchs' colleagues

We found five more compensation records of executives who worked with Henry J. Fuchs at BioMarin Pharmaceutical in 2019.

2019

Jean-Jacques Bienaim

BioMarin Pharmaceutical

Chief Executive Officer

2019

Robert Baffi

BioMarin Pharmaceutical

President, Global Manufacturing amp; Technical Operations

2019

Jeff Ajer

BioMarin Pharmaceutical

Executive Vice President, Chief Commercial Officer

2019

Daniel Spiegelman

BioMarin Pharmaceutical

Chief Financial Officer

2019

Brian Mueller

BioMarin Pharmaceutical

Chief Financial Officer

News

You may also like